RedHill Biopharma (RDHL) Operating Leases (2019 - 2024)
Historic Operating Leases for RedHill Biopharma (RDHL) over the last 6 years, with Q4 2024 value amounting to $3000.0.
- RedHill Biopharma's Operating Leases fell 9934.07% to $3000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $3000.0, marking a year-over-year decrease of 9934.07%. This contributed to the annual value of $3000.0 for FY2024, which is 9934.07% down from last year.
- Per RedHill Biopharma's latest filing, its Operating Leases stood at $3000.0 for Q4 2024, which was down 9934.07% from $455000.0 recorded in Q4 2023.
- In the past 5 years, RedHill Biopharma's Operating Leases registered a high of $6.4 million during Q4 2022, and its lowest value of $3000.0 during Q4 2024.
- Its 5-year average for Operating Leases is $2.7 million, with a median of $2.6 million in 2021.
- In the last 5 years, RedHill Biopharma's Operating Leases skyrocketed by 15031.08% in 2022 and then plummeted by 9934.07% in 2024.
- RedHill Biopharma's Operating Leases (Quarter) stood at $3.8 million in 2020, then crashed by 32.39% to $2.6 million in 2021, then skyrocketed by 150.31% to $6.4 million in 2022, then tumbled by 92.94% to $455000.0 in 2023, then plummeted by 99.34% to $3000.0 in 2024.
- Its Operating Leases was $3000.0 in Q4 2024, compared to $455000.0 in Q4 2023 and $6.4 million in Q4 2022.